Report
Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-1)
| العنوان: | Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-1) |
|---|---|
| المصدر: | A Phase 2, Randomized Study to Evaluate the Optimized Dose, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab for Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Patients Who Have Progressed After an Immune Checkpoint Inhibitor Containing Regimen in First-Line HCC |
| Other URLs: | https://vivli.org/ourmember/abbvie/ |
| قاعدة البيانات: | ClinicalTrials.gov |
| ResultId |
1 |
|---|---|
| Header |
edsclt ClinicalTrials.gov edsclt.NCT05822752 1117 2 Report report 1116.54992675781 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsclt&AN=edsclt.NCT05822752&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => https://clinicaltrials.gov/study/NCT05822752 [Name] => EDS – ClinicalTrials.gov [Category] => fullText [Text] => View record in ClinicalTrials.gov [MouseOverText] => View record in ClinicalTrials.gov ) ) |
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-1)
)
Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => A Phase 2, Randomized Study to Evaluate the Optimized Dose, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab for Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Patients Who Have Progressed After an Immune Checkpoint Inhibitor Containing Regimen in First-Line HCC ) Array ( [Name] => URL [Label] => Other URLs [Group] => URL [Data] => https://vivli.org/ourmember/abbvie/ ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Languages] => Array
(
[0] => Array
(
[Text] => English
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-1)
[Type] => main
)
)
)
[BibRelationships] => Array
(
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 02
[M] => 01
[Type] => published
[Y] => 2025
)
)
)
)
)
)
)
|
| IllustrationInfo |